Mark J. Ratain to Aminopyridines
This is a "connection" page, showing publications Mark J. Ratain has written about Aminopyridines.
Connection Strength
0.350
-
Lorlatinib Exposed: A Far From Optimal Dose. Clin Pharmacol Ther. 2022 06; 111(6):1195-1196.
Score: 0.200
-
Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial. Br J Cancer. 2018 04; 118(8):1042-1050.
Score: 0.151